pharma&
Ronald Schwarz is currently working as the European Pricing and Market Access Director at pharma& since May 2023. Prior to this, Ronald held the same position at Clovis Oncology from July 2021 to February 2023. With a background in market access and healthcare consulting, Ronald has also worked at IQVIA as an Associate Market Access Director, Quintiles Commercial Germany GmbH as a Market Access Consultant, and EPC HealthCare in various roles including Senior Consultant and Projektkoordinator. Ronald holds a Master's degree in International Pharmacoeconomics and Health Economics from Cardiff University and a Diplom Betriebswirt (FH) in Gesundheitsökonomie from Hochschule Fresenius. Ronald also completed an Ausbildung zum Chemisch Technischer Assistenten from Hochschule Fresenius.
This person is not in any teams
This person is not in any offices
pharma&
1 followers
pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines through our agile and fully integrated business model, guaranteeing the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Whether a former blockbuster or niche medicine, we acquire the worldwide rights to specialty treatments to secure long-term access to established and essential medicines across various specialized therapy areas, doing whatever it takes to maintain and develop the value of these medicines for all who depend on them. We’ve acquired and integrated 11 medicines over the past five years, expanding our portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. Our unique, fully integrated model across pharma&’s subsidiaries, joint ventures, and partners enables us to provide our portfolio of medicines to eligible healthcare providers and patients worldwide, spanning the continuum of manufacturing, distribution, administration/access, and patient support.